- Platform licensed to Chiesi for developing drugs
- Will receive $3 million upfront, and as much as $138 million in additional milestones and undisclosed royalties
- Has inhouse development programs targeting neurological diseases
What Bioasis Technologies does:
Bioasis Technologies Inc (CVE:BTI) (OTCQB:BIOAF) is a biopharma company developing the xB3 platform to aid in the delivery of molecules to the brain, and the treatment of brain cancers and neurodegenerative diseases.
The blood-brain barrier plays an indispensable role in protecting the brain from blood-borne disease. However, it also blocks crucial medicines from reaching the brain posing an epic challenge to treating neurological diseases.
Scientists at Bioasis have worked for over a decade to develop the patented xB3 platform, which helps small molecules shuttle across the blood-brain barrier (BBB) safely. Like a key designed to open a lock, the xB3 platform unlocks the door to the blood-brain barrier, allowing compounds into the brain. In a nutshell, the xB3 platform uses a small peptide to ferry molecules across the BBB in a process called receptor-mediated transcytosis.
The Guilford, Connecticut-based company’s inhouse drug programs are designed to develop treatments for neurological diseases. The lead program, xB3-001, is in preclinical development for brain metastases in HER2+ metastatic breast cancer. Bioasis is also working on xB3-002 aimed at treating glioblastoma, one of the most aggressive cancers originating in the brain, with 80% of diagnosed malignant brain tumors being gliomas.
The company has additional preclinical programs in pain, neurodegenerative diseases and rare diseases.
How is it doing:
At the end of June, Bioasis struck an agreement with the Chiesi Group to license its xB3 platform technology to the research giant for the development of drugs targeting lysosomal storage disorders (LSDs), which are inherited diseases caused by an abnormal build-up of toxic material in the body's cells due to enzyme deficiencies. People with lysosomal storage disorders lack specific enzymes that break down certain lipids (fats) or carbohydrates (sugars) in the body.
Chiesi will use the platform to develop drugs for four LSDs, and in return, Bioasis will receive $3 million upfront and up to $138 million in additional milestones and undisclosed royalties. According to the company, the Chiesi Group will be responsible for all costs associated with research, development and commercialization of the four undisclosed LSD programs.
Bioasis CEO Deborah Rathjen has said that the neurological complications of LSDs remain largely untreatable when peripheral symptoms of diseases respond to enzyme replacement therapy.
“Our xB3 BBB drug delivery platform has the potential to significantly advance the treatment of LSDs and the use of enzyme replacement therapy, solving one of the major unmet needs and improving the lives of patients,” she has pointed out.
Meanwhile, Bioasis has commissioned Bluestar BioAdvisors to provide a commercial assessment of its lead drug xB3-001, developed for the treatment of HER2+ cancers and brain metastases. Bluestar BioAdvisors reported that when used strictly to treat HER2+ breast cancer and brain metastases, xB3-001 could generate nearly $440 million in annual worldwide revenue.
However, the company said preclinical data suggests that xB3-001 is likely to perform outside the brain as well as intravenous drug Herceptin that is part of a chemotherapy regimen. Therefore, xB3-001 may have the potential to become the standard of care for all patients with HER2+ breast cancer for which Herceptin is prescribed.
Bluestar BioAdvisors pegs this larger market to be as high as $12.4 billion annually for all treatments of HER2+ breast cancer worldwide. With an estimated 30% share of this market, xB3-001 could produce annual revenue of $3.7 billion, so has blockbuster potential.
For the time being, xB3-001 has investigational new drug (IND) status enabling studies, and the company will require additional funds to advance it. As additional funding is secured, it is likely to bring forward milestones for xB3-001, in particular the IND filing with the US Food and Drug Administration (FDA) which is currently anticipated towards the end of the calendar year 2021.
- Expect partnerships for the xB3 drug delivery platform and licensing deals
- Several pipeline programs expected to reach key milestones
- New data in coming months to drive fresh partnership interest
- Data readout for xB3-007 being developed for treating Gaucher disease, GBA gene conditions, including Parkinson’s and Lewy Body Dementia
- A new undisclosed program targeting a form of dementia to reach preclinical proof-of-concept
What the broker says:
Analysts at Edison Investment Research recently modeled a higher valuation for Bioasis driven by its strategic alliance with Chiesi Global Rare Diseases.
“We see this as a major validation of the platform and for additional future licensing potential,” said Edison analyst Nathaniel Calloway. “We increased our valuation to C$60.1 million or C$0.89 per basic share, from C$47.8 million or C$0.71 per basic share, driven by the addition of the Chiesi partnership to our model.”
Edison Research noted that the xB3 platform may offer an “attractive solution” to improving central nervous system (CNS) drug activity because it is entirely modular.
“Enzyme replacement therapies have already been developed for a range of lysosomal storage disorders, and the development of a brain penetrant derivative of these drugs could be as simple as producing a conjugate to the xB3 peptide developed by the company,” said Calloway.
Edison also emphasized that the value of the xB3 platform is both in the “wide array of cargo that can be delivered” as well as the “rate of transfer,” which is “significantly higher than other methods that have been tried, at least in model systems.”
What the boss says:
“The xB3 platform is a very versatile, high capacity delivery system able to deliver antibodies, enzymes, siRNA as well as small molecules across the BBB. We believe that xB3 has the potential to deliver effective treatments into the brain for a very large number of conditions such as Alzheimer’s disease and other forms of dementia, Parkinson’s disease as well as for the treatment of brain cancers,” Bioasis CEO Deborah Rathjen has told Proactive.
“Our alliance with Chiesi represents a further validation for Bioasis’ technology and endorses our current strategic priorities. We won’t stop at this deal – will continue with our business development activities which have received a significant boost since the Chiesi deal. We are also advancing our preclinical programs and they are still a top priority for us. We are aiming to reach several preclinical milestones as we round out FY 2021,” she added.
Contact the author Uttara Choudhury at firstname.lastname@example.org
Follow her on Twitter: @UttaraProactive